|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 16, 2017 ) Chronic myeloid leukemia (CML) , also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 18Number of Products under Development by Companies, H1 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 18Number of Products under Development by Companies, H1 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 18Number of Products under Development by Companies, H1 2017
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 18Number of Products under Development by Companies, H1 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/chronic-myelocytic-leukemia-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) .
- The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834319/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AbbVie Inc
Altor BioScience Corp
arGEN-X BV
Ariad Pharmaceuticals Inc
Array BioPharma Inc
Astex Pharmaceuticals Inc
Atara Biotherapeutics Inc
Bio-Path Holdings Inc
BioLineRx Ltd
BioSight Ltd
BLR Bio LLC
Boston Biomedical Inc
Bristol-Myers Squibb Company
Cantargia AB
Celgene Corp
Cellectar Biosciences Inc
Cellectis SA
Cielo Therapeutics Inc
Constellation Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
Deciphera Pharmaceuticals LLC
Eisai Co Ltd
EpiZyme Inc
Galena Biopharma Inc
Gamida Cell Ltd
GlaxoSmithKline Plc
GlycoMimetics Inc
Hovione FarmaCiencia SA
Hybrigenics SA
Ilyang Pharmaceutical Co Ltd
Immune Pharmaceuticals Inc
Incyte Corp
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
JW Pharmaceutical Corp
Karyopharm Therapeutics Inc
Lixte Biotechnology Holdings Inc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
Natco Pharma Ltd
Novartis AG
OncoImmune Inc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Oribase Pharma
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Phylogica Ltd
Selvita SA
Shenogen Pharma Group Ltd
SignalChem Lifesciences Corp
Stemline Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Synactix Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
TRACON Pharmaceuticals Inc
Tragara Pharmaceuticals Inc
VioQuest Pharmaceuticals Inc
Xencor Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834319/discount
List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 19
Number of Products under Development by Companies, H1 2017 21
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 22
Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 23
Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 24
Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 25
Number of Products under Development by Universities/Institutes, H1 2017 26
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 28
Products under Development by Companies, H1 2017 29
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 30
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 31
Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 32
Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 33
Products under Development by Universities/Institutes, H1 2017 34
Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 35
Number of Products by Stage and Target, H1 2017 37
Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 38
Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 39
Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 40
Number of Products by Stage and Mechanism of Action, H1 2017 42
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 43
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 44
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 45
Number of Products by Stage and Route of Administration, H1 2017 47
Number of Products by Stage and Molecule Type, H1 2017 49
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H1 2017 50
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corp, H1 2017 50
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H1 2017 51
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017 52
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc, H1 2017 53
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H1 2017 53
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1 2017 54
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, H1 2017 54
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, H1 2017 55
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd, H1 2017 55
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BLR Bio LLC, H1 2017 56
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical Inc, H1 2017 56
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2017 57
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H1 2017 57
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corp, H1 2017 58
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectar Biosciences Inc, H1 2017 58
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectis SA, H1 2017 59
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cielo Therapeutics Inc, H1 2017 59
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H1 2017 60
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 60
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 61
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co Ltd, H1 2017 61
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme Inc, H1 2017 62
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma Inc, H1 2017 62
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, H1 2017 63
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2017 63
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics Inc, H1 2017 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hovione FarmaCiencia SA, H1 2017 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics SA, H1 2017 65
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2017 65
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H1 2017 66
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corp, H1 2017 66
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 67
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, H1 2017 67
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc, H1 2017 68
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corp, H1 2017 68
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H1 2017 69
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017 69
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mesoblast Ltd, H1 2017 70
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 70
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Ltd, H1 2017 71
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H1 2017 71
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoImmune Inc, H1 2017 72
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoTherapy Science Inc, H1 2017 72
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 73
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Oribase Pharma, H1 2017 73
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc, H1 2017 74
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar SA, H1 2017 74
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corp, H1 2017 75
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Phylogica Ltd, H1 2017 75
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita SA, H1 2017 76
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd, H1 2017 76
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by SignalChem Lifesciences Corp, H1 2017 77
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics Inc, H1 2017 77
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 78
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Synactix Pharmaceuticals Inc, H1 2017 78
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Syndax Pharmaceuticals Inc, H1 2017 79
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 79
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 80
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Tragara Pharmaceuticals Inc, H1 2017 80
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by VioQuest Pharmaceuticals Inc, H1 2017 81
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Xencor Inc, H1 2017 81
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 463
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..1) , H1 2017 464
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..2) , H1 2017 465
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..3) , H1 2017 466
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2017 467
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2017 (Contd..1) , H1 2017 468
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834319/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
